Quarterly report · Q2
2784.TEDINET S100S6JK
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.43T | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥2.70T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.33T | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥16.0bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥10.2bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥17.3bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥32.8bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥11.5bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥17.4bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥11.1bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥11.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥25.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥7.0bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥11.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥7.0bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥1.43T | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥1.34T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.33T | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥960.7bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥851.5bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥465.6bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥488.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥481.9bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥186.2bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥160.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥184.8bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥158.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥168.2bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥179.1bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥63.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥13.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥10.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥8.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥20.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥15.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥29.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥12.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥6.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥60.29 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥40.57 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥127.42 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥34.6 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.1 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 32.6% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.4% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.1% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥16.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥16.9bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | ¥269m |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.27T |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.26T |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥8.9bn |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥26.0bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥18.3bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥7.7bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥186m |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥18.2bn |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥18.2bn |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥279m |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥133.3bn |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥133.1bn |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥275m |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥1.44T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥1.43T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥16.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥15.7bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥15.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥15.2bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | ¥245m |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥1.18T |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.17T |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥8.3bn |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥8.0bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥23.6bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥17.0bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥6.6bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥842m |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥17.9bn |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥17.9bn |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥14m |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥124.1bn |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥123.8bn |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥305m |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥1.35T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥1.33T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥15.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥10.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 538
| Item | Context | Value | Unit |
|---|---|---|---|
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 9981000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | 245000000 | JPY |
| Operating income | Prior1YTDDuration | 10227000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 1258269000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 133075000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02962-000ManufacturingBusinessReportableSegmentsMember | 18327000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02962-000MedicalRelatedBusinessReportableSegmentsMember | 18183000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 1427856000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 1427856000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 8919000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 275000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02962-000ManufacturingBusinessReportableSegmentsMember | 7687000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02962-000MedicalRelatedBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 16882000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -16882000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 1267188000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 133350000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02962-000ManufacturingBusinessReportableSegmentsMember | 26015000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02962-000MedicalRelatedBusinessReportableSegmentsMember | 18183000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 1444739000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -16882000000 | JPY |
| Net sales | CurrentYTDDuration | 1427856000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 13796000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 1466000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02962-000ManufacturingBusinessReportableSegmentsMember | 186000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E02962-000MedicalRelatedBusinessReportableSegmentsMember | 279000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 15729000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | 269000000 | JPY |
| Operating income | CurrentYTDDuration | 15998000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-11-10 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第21期第２四半期(自 2023年７月１日 至 2023年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)アルフレッサ ホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | Alfresa Holdings Corporation | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 荒川 隆治 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都千代田区大手町一丁目１番３号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03-5219-5100 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)代表取締役 副社長社長補佐 総務・財務企画・コーポレートコミュニケーション・コンプライアンス担当岸田 誠一 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都千代田区大手町一丁目１番３号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-5219-5100 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)代表取締役 副社長社長補佐 総務・財務企画・コーポレートコミュニケーション・コンプライアンス担当岸田 誠一 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E02962 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 27840 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)アルフレッサ ホールディングス株式会社 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |